Emergence of a peak in early infant mortality due to HIV/AIDS in South Africa by Bourne, David E et al.
C
Emergence of a peak in early infant mortality due to
HIV/AIDS in South Africa
David E. Bournea, MaryLou Thompsona,b, Linnea L. Brodya,f,
Mark Cottonc, Beverly Drapera, Ria Laubscherd,
M. Fareed Abdullahe and Jonny E. Myersaopyright © L










ISSObjectives: South Africa has among the highest levels of HIV prevalence in the world.
Our objectives are to describe the distribution of South African infant and child
mortality by age at fine resolution, to identify any trends over recent time and to
examine these trends for HIV-associated and non HIV-associated causes of mortality.
Methods: A retrospective review of vital registration data was conducted. All registered
postneonatal deaths under 1 year of age in South Africa for the period 1997–2002 were
analysed by age in months using a generalized linear model with a log link and Poisson
family.
Results: Postneonatal mortality increased each year over the period 1997–2002. A
peak in HIV-related deaths was observed, centred at 2–3 months of age, rising
monotonically over time.
Conclusion: We interpret the peak in mortality at 2–3 months as an indicator for
paediatric AIDS in a South African population with high HIV prevalence and where
other causes of death are not sufficiently high to mask HIV effects. Intrauterine and
intrapartum infection may contribute to this peak. It is potentially a useful surveillance
tool, not requiring an exact cause of death. The findings also illustrate the need for early
treatment of mother and child in settings with very high HIV prevalence.
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South Africa is currently experiencing a severe HIV/AIDS
epidemic, with corresponding high infant mortality. The
mean infant mortality rate in South Africa for the period
1993–1998 was 45.4, which is rather low compared with
other sub-Saharan African countries [1]. The prevalence of
HIV infection among women attending antenatal clinics in
the public sector was estimated to be 7.6% in 1994,
increasing to 22.8% in 1998, and peaking at 30.3% by 2005
[2]. Prevention of mother-to-child transmission pro-
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Antiretroviral (ARV) medication was not generally
available in public sector facilities in most of South Africa
until as late as 2004. In the absence of intervention
measures, it is estimated that the proportion of infants
infected with HIV through mother-to-child transmission
is between 25 and 45% [6]. In an early study from the
KwaZulu-Natal Province conducted in 1992, the trans-
mission proportion was 34% [7], and in utero infection, in an
era before ARV administration, has been reported as 27%
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102 AIDS 2009, Vol 23 No 1trends over recent time. We assess trends in HIV-associated
and non HIV-associated causes of mortality. South Africa
provides a unique environment to examine these
objectives, as there is a combination of an endemic high
prevalence of HIV and the availability of a relatively
sophisticated vital statistics system.Methods
Data sources
We obtained South African infant mortality counts by age
in months under 5 years for the period 1997–2002 as a
special tabulation from Statistics South Africa (STATS
SA), including underlying cause of death, coded to the
International Classification of Diseases (ICD-10) at the
three-character level [9]. Although STATS SA data are
coded to three characters of the ICD, this does not
necessarily mean that these diagnoses are correct at this
level. In fact, there is substantial misclassification at this
apparent level of detail, and only the broadest of
categories (the Chapter codes) will retain any validity
[10]. On the basis of ICD-10 Chapter codes, we divided
all postneonatal deaths under 1 year of age into two
groups – those likely to be, and those not likely to be,
caused by an HIV infection in the child (Table 1). Chapter
codes in the group unlikely to be related to HIV/AIDS
are least liable to be subject to misclassification. The
group likely to be related to HIV/AIDS contains all the
other Chapter codes and is more liable to misclassifi-
cation. It includes HIV/AIDS as a reported cause of death
as well as perinatal (Chapter XVI) and unclassified
(Chapter XVIII) causes. HIV/AIDS as a reported cause of
death is subject to serious underreporting in South Africa
[11]. We believe that significant numbers of the deaths
recorded in the unclassified and perinatal categories will,
in fact, be HIV-related. Unclassified deaths constitute a
small proportion, 2% on average, of all postneonatal
deaths, whereas on average 76% of deaths at 1–11 months
were attributed to perinatal causes. STATS SA has
acknowledged misclassification in the perinatal Chapter
[12]. Although there is potential for misclassification in
this grouping, this can only serve to dilute any HIV-
related trends in the data.pyright © Lippincott Williams & Wilkins. Unauthor
Table 1. Causes of infant death (the International Classification of




Causes unlikely to be associated
with HIV/AIDS
Infectious/parasitic Neoplasms







EarDeaths recorded before age 1 month were excluded from
analyses because of the potential misclassification of live
and stillbirths. During the time period under study, the
number of births remained approximately static at about
1.1 million per annum [13].
Statistical analysis
The following generalized linear model (GLM) with a
log link and Poisson family [14] was used to model
postneonatal HIV/AIDS-associated mortality counts
under 1 year of age for the period 1997–2002:
lnðEðY ijÞÞ ¼ a0 þ b1 jþ b2M þ g1iþ g2R
where Yij is the number of deaths at age j months in year i;
M¼ ( j–2.5) for j 2.5, M¼ 0 otherwise; i¼ 0 for 1997,
i¼ 1 for 1998 and so on; R¼ i if age¼ 2–3 months,
R¼ 0 otherwise. For a given year, this models the annual
age-specific mortality rate (on the log scale) by a linear
spline in age with a knot at 2.5 months of age, that is, by
two straight lines with possibly different slope before (b1)
and after (b1þb2) 2.5 months of age. The mortality trend
over years at each age is modelled separately for age at
death 2–3 months (g1þ g2) and other ages (g1). Hence
the null hypothesis H0: b2¼ 0 assesses whether there is a
change at 2–3 months in the trend in age-specific
mortality within a given year. The null hypothesis H0:
g2¼ 0 assesses whether the change in mortality over time
at ages 2–3 months is different from those at other ages.
Robust variance estimation [15] was used to accommo-
date correlation in the mortality counts and possible
deviations from the Poisson mean-variance structure.
Z-statistics (parameters divided by their robust standard
errors) were used to test the above hypotheses. Statistical
significance was defined as P value less than 0.05. Analyses
were carried out using Stata statistical software, Version
9.1 [16].Results
Figure 1 shows the changing mortality pattern from birth
to 5 years of age for the period 1997–2002. Clearly
evident is the high neonatal mortality, an emerging peak
of mortality centred at ages 2–3 months, and thereafter a
decline in mortality up to 5 years of age. In 1997, there
were 11 469 recorded neonatal deaths in South Africa
before age 1 month, representing 43.8% of South African
deaths within the first year of life. By 2002, these had
increased in absolute terms to 12 152 recorded infant
deaths before age 1 month, when neonatal deaths
constituted only 33.3% of 2002 deaths within the first
year of life. However, between 1997 and 2002, deaths at
2–3 months of age increased from 30.5 to 35.5% of the
postneonatal mortality within the first year of life. In
1997, there were 7322 deaths at between 1 and 5 years of
age; by 2002, this had increased to 11 917 deaths.ized reproduction of this article is prohibited.
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Fig. 2. Graphical representation of likely HIV/AIDS-related
deaths, at ages 1–11 months, in South Africa during 1997–
2002.
Fig. 1. Graphical representation of total deaths, at ages
0–60 months, in South Africa during 1997–2002.An increase over time in the number of postneonatal
infant deaths likely to be associated with HIV/AIDS at all
ages under 1 year is apparent (Fig. 2), with a more marked
increase at ages 2–3 months. Table 2 shows the estimated
mortality rate ratios corresponding to the fitted
generalized linear model. The GLM analysis indicated
that, in each calendar year, expected mortality increased
significantly with increasing age of death up to 2.5
months and then decreased significantly thereafter, that is,
a peak in mortality exists at age 2–3 months. The null
hypothesis that there is no change in trend in mortality
after 2–3 months (H0: b2¼ 0) is rejected (P< 0.0005).
Further, the rate of increase in mortality from year to year
at ages 2–3 months was significantly greater than that at
other ages of death (H0: g2¼ 0 is rejected, P< 0.0005),
that is, the peak was accelerating. A more richly
parameterized model with main effects for year and
age (in months) provided a better fit to the data (analysis
not shown). However, the conclusions from the model
summarized in Table 2, which has the advantages of
parsimony and ease of interpretation, are entirely
consistent with those for the more complex model.
Postneonatal infant mortality counts not associated with
HIV/AIDS remained relatively stable over the time
period under consideration and showed no indication of a
peak at age 2–3 months (Fig. 3). Mortality across age of
death within each calendar year showed a significantopyright © Lippincott Williams & Wilkins. Unauth
Table 2. Estimated mortality rate ratios from generalized linear model at
Estim
Within a calendar year, corresponding to 1 month increase in age:
Prior to 2.5 months of age (eb1 )
After 2.5 months of age (eb1þb2 )
At a given age, comparing successive years:
Age 6¼ 2–3 months (eg1 )
Age¼2–3 months (eg1þg2 )
CI, confidence interval.decline from age 1 month (P< 0.0005), with no change
in that downward trend at 2–3 months of age (P¼ 0.57).Discussion
The typical mortality pattern by age during the first year
of life shows a decline with increasing age. We have,
however, observed the emergence of a substantial and
monotonically increasing peak in the South African
population all-cause mortality during the early post-
neonatal period, as well as in those deaths, which are more
likely to be associated with HIV. For deaths unlikely to be
associated with HIV/AIDS, there was no peak in the early
postneonatal period, nor any increase over time,
indicating that an increase in registration efficiency of
infant deaths was not an artefactual cause of the overall
observed peak in deaths. In addition, it does not seem
plausible that increases in registration over time could lead
to recorded mortality at ages 2–3 months increasing at a
greater rate than the recorded mortality at other months
of age. Although we acknowledge that the ICD-10 codes
that we have grouped to represent HIV/AIDS-related
causes of death are subject to misclassification, we
nevertheless believe that this misclassification would only
serve to dilute any HIV/AIDS-related trends in mortality.
In support of this contention, we have carried outorized reproduction of this article is prohibited.
ages 1–11 months during 1997–2002.
ated mortality rate ratio (95% CI) P-value
1.12 (1.07, 1.17) <0.0005
0.85 (0.84, 0.86) <0.0005
1.07 (1.06, 1.09) <0.0005
1.16 (1.15, 1.18) <0.0005
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Fig. 3. Graphical representation of deaths unlikely to be
related to HIV/AIDS, at ages 1–11 months in South Africa
during 1997–2002.separate analyses for two HIV/AIDS-related ICD-10
Chapter codes, which are unlikely to be subject to
misclassification: infectious and parasitic diseases (Chapter
I) and diseases of the blood and immune mechanism
(Chapter III). In these data, we observe an even more
pronounced increasing peak in mortality at ages 2–3
months (data not shown). These observations constitute
convincing evidence for HIV/AIDS causation.
Although we did not a priori anticipate a peak in
postneonatal mortality at ages 2–3 months, the consistent
presence of this peak in each year over the period under
consideration makes it extremely unlikely to be a chance
finding. Newell et al. [17] previously documented
cumulative mortality of HIV-infected and uninfected
infants born to HIV-infected mothers in Africa. Although
they did not discern this peak, our results led us to
transform their estimated cumulative mortality estimates
into age-specific mortality probabilities, which showed a
similar peak at about 4 months of age. To our knowledge,
there are no other reports in the literature relating to this
peak in early infant mortality in settings of high HIV
prevalence.
The magnitude of this peak in mortality at the population
level is substantial. It is also notable that no other country
experiencing a severe AIDS epidemic has been capable of
analysing infant mortality at this fine age resolution. If
traditional child mortality indicators such as neonatal and
infant mortality had been used, the observed peak would
have been missed. Cohort studies have also focussed on
conventional summary measures such as cumulative
mortality as opposed to age-specific hazards.
Although such a peak in mortality is unlikely to be detected
in poorly resourced settings without a relatively sophis-
ticated vital registration system [18], it is also unlikely to
arise in well resourced settings with low HIV prevalence
and good healthcare, where the numberof deaths would bepyright © Lippincott Williams & Wilkins. Unauthortoo small to discern such a pattern. In the whole of North
America and Western Europe, there is approximately one
case of vertical transmission of HIV daily compared with
1700 in sub-Saharan Africa [19]. It still needs to be shown
whether this peak will emerge in other less developed
settings with extremely high infant mortality.
There is some local epidemiological evidence for
increased mortality due to HIV/AIDS during the first
2 years of life compared with the period from 2 to 5 years
of age. The earlier group is thought to have become
infected in utero or during delivery, whereas the latter is
thought to become infected through breastfeeding [20].
A healthy mother provides maternal immunity to her
infant through placental transfer and through breast milk.
By approximately 3 months after birth, an infant’s
maternally acquired immunity is in decline, whereas the
infant’s own immunity, which begins development
in utero, is still very immature [21]. In the presence of
in-utero HIV infection, the infant’s immunity is likely to
be further compromised.
Studies [22–24] have also shown that infants born to
mothers who are HIV positive receive deficient maternal
immunity as a result of deficient placental transfer of
maternal antibodies, or because an HIV-positive mother
may simply have levels of antibodies too low for sufficient
transfer. Further, studies [25,26] suggest that an HIV-
induced deficient maternal immune system fails to
adequately support the development of a competent
immune system in infants. Studies have also shown an
increase in mortality in HIV-uninfected infants born to
HIV-positive mothers [27]. Kuhn et al. [24] have linked
this with advanced maternal disease in a Zambian
cohort.
Further evidence indicating immunological immaturity
in neonates has been shown for nef-deleted SIV infection,
which, while not virulent in adult macaques, is highly
pathogenic in neonatal macaques [28]. Factors permitting
high viral replication in infants include a larger pool of
CD4þ T-cells, a large thymus, delayed development of
cytotoxic lymphocyte activity, and antibody-dependent
cytotoxicity [29]. Infants cannot suppress HIV replication
as effectively as adults. In a prospective study comparing
newly infected Kenyan adults and infants, the mean peak
HIV-1 RNA was significantly higher in infants than
adults, as was the mean set point level, indicating poorer
ability to control HIV replication in infants. Further
evidence is that the viral set point in infants infected later
in life through breastfeeding was far lower than that in
infants infected earlier [30]. Evidence that early initiation
of ARV therapy (by 6 weeks of age) reduces mortality by
75% compared with waiting for immunological markers
to be below threshold values [31] corroborates the
interpretation from this study that infants born infected
with HIV are at particular risk of dying a few months
after birth.ized reproduction of this article is prohibited.
C
Emergence of a peak in early infant mortality Bourne et al. 105In the present study, the sharp increase in mortality seen at
2–3 months is likely to be a result of the particular
immunological vulnerability of HIV-infected neonates at
this age. The most likely event that causes the peak is the
loss of acquired maternal immunity at 2–3 months in
children who have either been infected in utero or
intrapartum. Another explanation could be acute retro-
viral syndrome from intrapartum infection, which would
manifest from approx 6 weeks of age – this has been
described in African infants [32].
By contrast, acquisition of HIV infection from breast milk
is likely to take place over an extended period of time, as
will the manifestation of the sequelae of infection leading
to death. We hypothesize that this particular mechanism
will not lead to a sharp peak of mortality, but is more likely
to lead to an extended tail of mortality beyond the peak
described here.
In populations similar to those of South Africa with high
HIV prevalence and where other causes of death are not
sufficiently high to mask HIVeffects, the observed peak in
mortality in early infancy, which is a new demographic
phenomenon, provides a potentially useful surveillance
tool for monitoring paediatric AIDS without requiring
explicitly diagnosed cause of death.Acknowledgements
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